Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708444 | 0.84 | ADRB2 (0.43) | ADRB2ADRB1ADRB3KCNH2L3MBTL1 | |
| SCHEMBL13708425 | 0.82 | ADRB2 (0.60) | ADRB2ADRB1ADRB3L3MBTL1BCHE | |
| SCHEMBL13708443 | 0.82 | ADRB2 (0.42) | ADRB2ADRB1ADRB3 | |
| SCHEMBL13708431 | 0.81 | ADRB2 (0.52) | ADRB2ADRB1ADRB3KCNH2BCHE | |
| SCHEMBL13708403 | 0.79 | ADRB2 (0.39) | ADRB2ADRB1ADRB3KCNH2L3MBTL1 | |
| SCHEMBL13708401 | 0.78 | MAPT (0.45) | ADRB2ADRB1ADRB3KCNH2L3MBTL1 | |
| SCHEMBL12995578 | 0.78 | ADRB2 (0.40) | ADRB2ADRB1ADRB3L3MBTL1BCHE | |
| SCHEMBL3978396 | 0.78 | ADRB2 (0.43) | ADRB2ADRB1ADRB3L3MBTL1MEN1 | |
| SCHEMBL13617672 | 0.76 | ADRB2 (0.51) | ADRB2ADRB1ADRB3 | |
| SCHEMBL14752729 | 0.75 | BCHE (0.40) | ADRB2BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.